REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

REPROCELL-USA

More Like This

Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026 ISSCR Annual Meeting in Montréal, Canada.

STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development

PR Newswire associated0

REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

CelluPro Receives EXCiPACT™ Certification for GMP-grade Cell Culture Media Manufacturing, Strengthening Global Biomanufacturing Supply Capabilities

PR Newswire associated0

Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance

*For research purposes only. Anticipated visual image of LiCellGrow. All features subject to change. (Graphic: Business Wire)

PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processes to Enhance Efficiency and Improve Cell Quality